Burden of T2D and Management Considerations for Older and Younger Adults

Opinion
Video

Medha Munshi, MD, and James Bailey, III, MD, FACE, ECNU, delve into the management and burden of type 2 diabetes (T2D). They shed light on the prevalence of the disease in older adults and its potential health impacts as patients age, while also addressing risk factors and considerations for younger patients as they progress in age.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

Grace Halsey
July 9th 2025
Article

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

Sydney Jennings
June 26th 2025
Article

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D

Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D

Sydney Jennings
June 23rd 2025
Article

ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults with Type 2 Diabetes / image credit ADA Julio Rosenstock, MD

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults With Type 2 Diabetes

Grace Halsey
June 23rd 2025
Article

ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.

© 2025 MJH Life Sciences

All rights reserved.